Menopause Treatment Market Outlook and Opportunities in Grooming Regions with Forecast 2032

Pune, India, July, 2023, MRFR Press Release/- Market Research Future (MRFR) has published a cooked research report on the “Global Menopause Treatment Market” that contains information from 2018 to 2032. 

Market Highlights

The global Menopause Treatment market is accounted to register a CAGR of 6.10% during the forecast period and is estimated to reach USD 17.3 Billion by 2032.

The Menopause Treatment Market pertains to the pharmaceuticals, therapies, and products targeted at managing symptoms and complications associated with menopause. It encompasses hormone replacement therapies, non-hormonal medications, lifestyle modifications, and alternative treatments designed to alleviate symptoms such as hot flashes, mood swings, and bone density loss experienced by women during menopause.

Key Players

MRFR recognizes the following companies as the key players in the global Menopause Treatment market— Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India),Teva Pharmaceuticals (Israel), Merck & Co. Inc. (US), and Abbott Laboratories (US).

Segment Analysis

The global Menopause Treatment market has been segmented based on Treatment and Distribution Channel.

On the basis of Treatment, the market is segmented into hormonal treatment as well as a non-hormonal treatment. Oestrogen, progesterone, and combinations are the three main types of hormonal therapy. The hormonal treatment segment controls the global market because hormone therapy is the most frequently recommended or prescribed drug for treating menopausal symptoms like vaginal dryness and hot flashes. Antidepressants and other sorts of non-hormonal treatments are available.

Based on Distribution Channel, the global Menopause Treatment market has been segmented into retail pharmacies, online stores and hospital pharmacies. Due to the rising number of women choosing to be admitted due to the availability of numerous cutting-edge technology and services in hospitals, the hospital pharmacy market segment gained the lead in 2019.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Menopause Treatment Market Research Report

Regional Analysis

The global Menopause Treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Menopause Treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Menopause Treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Menopause Treatment market comprises of Middle East, Africa, and Latin America.

Due to the rise in female urogenital difficulties and vasomotor symptoms, new drug releases, and the presence of a developed healthcare sector with up-to-date infrastructure, the American market has been leading since 2019. The steadily growing number of women over 60, the high prevalence of an unhealthy lifestyle, and the rising use of innovative pharmaceuticals all benefit the American market. Supportive government programmes for women's health in the United States and the resulting rise in awareness help the local market's potential for growth.

Due to increased levels of interest in women's health and an increase in joint ventures between players and local distributors and businesses, Asia Pacific has the potential to experience the quickest growth rate over the evaluation period. Women are becoming more digitally adept and technologically literate in the area. The region's growing working women's population is well-versed in healthcare digitization and uses smartphones, making them a potential target market

Key Findings of the Study

• The global Menopause Treatment market is expected to reach USD 17.3 Billion by 2032, at a CAGR of 6.10% during the forecast period.


• the American market has been leading since 2019. The steadily growing number of women over 60, the high prevalence of an unhealthy lifestyle, and the rising use of innovative pharmaceuticals all benefit the American market.


• Based on Treatment, The hormonal treatment segment controls the global market because hormone therapy is the most frequently recommended or prescribed drug for treating menopausal symptoms like vaginal dryness and hot flashes.


• Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India),Teva Pharmaceuticals (Israel), Merck & Co. Inc. (US), Abbott Laboratories (US).